When was AskBio founded?

AskBio was founded in 2001 and raised its 1st funding round 7 years after it was founded.

Where is AskBio located?

AskBio is headquartered in Durham, United States.

Who is the current CEO of AskBio?

Sheila Ann Mikhail of AskBio. They have also founded 1 company.

How many employees does AskBio have?

As of May 31, 2026, the latest employee count at AskBio is 527.

Is AskBio a funded company?

AskBio is a funded company, having raised a total of $235M across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 26, 2008.

When was the latest funding round of AskBio?

AskBio's latest funding was a $***** Grant (prize money) round on Sep 02, 2020, with participation from 1 investor.

Where does AskBio rank among its competitors?

AskBio ranks 43rd amongst 3193 active competitors, of which 1102 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Biogen, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of AskBio?

AskBio's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Biogen secured the most recent funding round in February, 2024.

AskBio - 2026 Company Profile, Team, Funding & Competitors

Q: Is AskBio an acquired company?

AskBio got acquired by Bayer on Oct 26, 2020.

Company Details

Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.

Website: www.askbio.com/
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2001

Location

Durham, United States

Stage

Acquired

Total Funding

$235M in 8 rounds

Latest Funding Round

Grant (prize money), Sep 02, 2020, $*****

Investors

TPG & 5 more

Ranked

43^rd among 3193 active competitors

Employee Count

527 as on May 31, 2026

Investment & Acquisitions

Brain Vectis & 1 more

Similar Companies

Jazz Pharmaceuticals & 913 more

Exit Details

Acquired by Bayer (Oct 26, 2020)

View AskBio's full profile

AskBio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
SYNPROMICS LTD CIN: 1739278 , United States, Active		$1M - $5M (As on May 15, 2018)	-	-

AskBio got acquired by Bayer on Oct 26, 2020 at an acquisition amount of $*****.

Click here to take a look at AskBio's acquisition in detail

AskBio has raised a total funding of $235M over 8 rounds. Its first funding round was on Sep 26, 2008. Its latest funding round was a Grant (prize money) round on Sep 02, 2020 for $*****. 1 investor participated in its latest round. AskBio has 6 institutional investors.

Here is the list of recent funding rounds of AskBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 02, 2020	5008846	Grant (prize money)	7995787	3732520	2066137	1341612
Apr 11, 2019	9020831	PE	9389720	4621071	3199727	1639068
Aug 15, 2014	2668254	Grant (prize money)	3398561	9919921	2697305	HHS

Access funding benchmarks and valuations. Sign up today!

View details of AskBio's funding rounds and investors

The founders of AskBio are Jude Samulski and Sheila Ann Mikhail. Sheila Ann Mikhail is the CEO of AskBio.

Here are the details of AskBio's key team members:

Jude Samulski: Co-Founder & CSO of AskBio.
Contact Info: 1 email address
Sheila Ann Mikhail: Co-Founder & CEO of AskBio.

View details of AskBio's Founder profiles and Board Members

AskBio's employee count trend

AskBio has 527 employees as of May 26. Here is AskBio's employee count trend over the years:

Uncover AskBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AskBio include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of AskBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Gershon Capital & 10 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 27 others	77/100
4th	Syngenta 2000, Basel (Switzerland), Acquired	Developer of technologies and sustainable farming practices for farmers	-	Analah Ventures, Europa	75/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
6th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
7th	Ginkgo Bioworks 2008, Boston (United States), Public	Autonomous labs for biotechnology, empowering scientists to design the living world	$796M	Viking Global Investors, Felicis Ventures ... & 53 others	74/100
8th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
10th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
43rd	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Columbus Venture Partners, Golden Valley Capital ... & 4 others	68/100